Correlation Between Viridian Therapeutics and Spero Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Viridian Therapeutics and Spero Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viridian Therapeutics and Spero Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Viridian Therapeutics and Spero Therapeutics, you can compare the effects of market volatilities on Viridian Therapeutics and Spero Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viridian Therapeutics with a short position of Spero Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viridian Therapeutics and Spero Therapeutics.

Diversification Opportunities for Viridian Therapeutics and Spero Therapeutics

-0.35
  Correlation Coefficient

Very good diversification

The 3 months correlation between Viridian and Spero is -0.35. Overlapping area represents the amount of risk that can be diversified away by holding Viridian Therapeutics and Spero Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Spero Therapeutics and Viridian Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viridian Therapeutics are associated (or correlated) with Spero Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Spero Therapeutics has no effect on the direction of Viridian Therapeutics i.e., Viridian Therapeutics and Spero Therapeutics go up and down completely randomly.

Pair Corralation between Viridian Therapeutics and Spero Therapeutics

Given the investment horizon of 90 days Viridian Therapeutics is expected to under-perform the Spero Therapeutics. In addition to that, Viridian Therapeutics is 1.18 times more volatile than Spero Therapeutics. It trades about -0.15 of its total potential returns per unit of risk. Spero Therapeutics is currently generating about -0.14 per unit of volatility. If you would invest  129.00  in Spero Therapeutics on August 27, 2024 and sell it today you would lose (13.00) from holding Spero Therapeutics or give up 10.08% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Viridian Therapeutics  vs.  Spero Therapeutics

 Performance 
       Timeline  
Viridian Therapeutics 

Risk-Adjusted Performance

8 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Viridian Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very conflicting fundamental indicators, Viridian Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.
Spero Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Spero Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

Viridian Therapeutics and Spero Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Viridian Therapeutics and Spero Therapeutics

The main advantage of trading using opposite Viridian Therapeutics and Spero Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viridian Therapeutics position performs unexpectedly, Spero Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will offset losses from the drop in Spero Therapeutics' long position.
The idea behind Viridian Therapeutics and Spero Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Bonds Directory
Find actively traded corporate debentures issued by US companies
Transaction History
View history of all your transactions and understand their impact on performance